Published in Cancer Res on March 01, 2004
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Many stimuli pull the necrotic trigger, an overview. Cell Death Differ (2011) 2.55
Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest (2009) 2.34
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2008) 1.54
Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*. Crit Care Med (2013) 1.51
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A (2004) 1.42
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Ther (2009) 1.25
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer (2006) 1.23
Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res (2009) 1.18
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res (2013) 1.06
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer (2006) 1.06
Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit Care (2009) 1.05
Biomarkers of apoptosis. Br J Cancer (2008) 1.01
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer (2010) 0.98
Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One (2011) 0.95
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia (2006) 0.92
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res (2008) 0.92
Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res (2010) 0.91
Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int (2013) 0.90
Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer (2009) 0.89
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer (2011) 0.88
Serum cytokeratin 18 as a biomarker for gastric cancer. Clin Exp Med (2012) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon (2013) 0.87
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. PLoS One (2009) 0.85
Persistent Chlamydia trachomatis infection of HeLa cells mediates apoptosis resistance through a Chlamydia protease-like activity factor-independent mechanism and induces high mobility group box 1 release. Infect Immun (2011) 0.85
Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis? World J Exp Med (2015) 0.85
A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death Dis (2013) 0.85
Hypoxic preconditioning potentiates the trophic effects of mesenchymal stem cells on co-cultured human primary hepatocytes. Stem Cell Res Ther (2015) 0.84
Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS One (2014) 0.84
Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiol Oncol (2011) 0.83
Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology (2013) 0.83
Hormesis, cell death, and regenerative medicine for neurode-generative diseases. Dose Response (2012) 0.82
Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS One (2012) 0.82
Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80
Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther (2015) 0.79
Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. J Hepatol (2016) 0.79
Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line. Invest New Drugs (2007) 0.77
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer (2012) 0.77
Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients. Exp Ther Med (2010) 0.76
Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol (2014) 0.76
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci (2015) 0.76
Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75
Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression. Iran J Cancer Prev (2016) 0.75
Propofol or sevoflurane anaesthesia does not affect hepatic integrity as assessed by the M30 & M65 cell death markers & liver enzymes. Indian J Med Res (2014) 0.75
Liver Injury and Endotoxemia in Male and Female Alcohol-Dependent Individuals Admitted to an Alcohol Treatment Program. Alcohol Clin Exp Res (2017) 0.75
Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells. PLoS One (2017) 0.75
Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci Rep (2017) 0.75
The transformation in biomarker detection and management of drug-induced liver injury. Liver Int (2017) 0.75
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin alfa (GGF2) Clinical Trials. Clin Pharmacol Ther (2017) 0.75
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol (2008) 2.97
Novel artificial neural network for early detection of prostate cancer. J Clin Oncol (2002) 2.88
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol (2006) 2.77
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol (2007) 2.39
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol (2006) 2.29
Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem (2002) 2.20
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol (2004) 1.89
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol (2004) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol (2011) 1.71
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer (2007) 1.67
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol (2004) 1.65
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol (2009) 1.60
Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest (2003) 1.60
Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate (2002) 1.56
Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer (2008) 1.55
Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol (2002) 1.54
Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology (2002) 1.51
Local active warming: an effective treatment for pain, anxiety and nausea caused by renal colic. J Urol (2003) 1.50
A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs (2002) 1.49
Perioperative, oncologic, and functional outcomes of laparoscopic renal cryoablation and open partial nephrectomy: a matched pair analysis. J Endourol (2011) 1.49
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology (2009) 1.45
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res (2007) 1.45
Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res (2004) 1.42
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A (2004) 1.42
Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy. Urology (2009) 1.41
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood (2013) 1.38
Open to debate. The motion: GnRH antagonists are the new way forward in hormonal therapy. Eur Urol (2009) 1.38
Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol (2006) 1.38
Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem (2002) 1.38
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer (2002) 1.30
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol (2005) 1.29
Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell (2005) 1.29
Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem (2004) 1.29
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett (2004) 1.25
Contemporary management of small renal masses. Eur Urol (2011) 1.19
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology (2004) 1.17
Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem (2012) 1.17
Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol (2012) 1.16
Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int (2007) 1.15
Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene (2003) 1.14
A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol (2009) 1.13
Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res (2007) 1.12
The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer (2007) 1.11
High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int (2012) 1.10
The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy. BJU Int (2008) 1.10
Loss of cell membrane integrity in puumala hantavirus-infected patients correlates with levels of epithelial cell apoptosis and perforin. J Virol (2006) 1.09
Repeat prostate biopsy: who, how and when?. a review. Eur Urol (2002) 1.09
Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Rev Med Chem (2007) 1.09
3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol (2008) 1.08
The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int (2011) 1.08
Clinical cancer proteomics: promises and pitfalls. J Proteome Res (2005) 1.07
Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol (2012) 1.07
A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound. Eur Urol (2007) 1.07
Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy. Drug Resist Updat (2005) 1.06
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells. Biochem Biophys Res Commun (2013) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.00
High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Med Microbiol Immunol (2011) 0.99
'Skipping' is still a problem with radiofrequency ablation of small renal tumours. BJU Int (2007) 0.99
Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer (2011) 0.99
High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol (2003) 0.99
An artificial neural network to predict the outcome of repeat prostate biopsies. Urology (2003) 0.98
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int J Cancer (2009) 0.98
Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur Urol (2002) 0.98
Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. BJU Int (2009) 0.97
Haemostasis in laparoscopy. Eur Urol (2006) 0.96
Whole slide images as a platform for initial diagnostics in histopathology in a medium-sized routine laboratory. J Clin Pathol (2012) 0.96
Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate (2004) 0.96
Nephrovesical subcutaneous ureteric bypass: long-term results in patients with advanced metastatic disease-improvement of renal function and quality of life. Eur Urol (2006) 0.96
Expertise under the microscope: processing histopathological slides. Med Educ (2014) 0.96
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology (2004) 0.94